Consensus Y-mAbs Therapeutics, Inc.

Equities

YMAB

US9842411095

Real-time Estimate Cboe BZX Other stock markets 10:14:42 2024-04-26 am EDT			5-day change	1st Jan Change
14.74 ^USD	-0.71%		-1.59%	+118.33%

Mar. 14	Y-mAbs Therapeutics Chief Financial Officer Bo Kruse to Resign	MT
Mar. 14	Y-mAbs Therapeutics, Inc. Announces Resignation of Bo Kruse as Executive Vice President, Secretary and Treasurer, Effective July 31, 2024	CI

Evolution of the average Target Price on Y-mAbs Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

754dd0fab41bbc990712.s7Ahy_2TE58amyiIXR8dU4JWg-pPwQ0M67UG8S9Iep4.x8Z5nc6rfdNX9E37LWkwGvJh6q81i0xBk_8xiHg8D_nw1lb7iet79y_ReQ~571ef5d8ee21b62ecff66615492133f6

Analyst Recommendations on Y-mAbs Therapeutics, Inc.

HC Wainwright Adjusts Price Target on Y-mAbs Therapeutics to $22 From $21, Keeps Buy Rating	Mar. 06	MT
Canaccord Genuity Raises Price Target on Y-mAbs Therapeutics to $26 From $22, Maintains Buy Rating	Mar. 04	MT
BMO Capital Adjusts Y-mAbs Therapeutics Price Target to $26 From $16, Maintains Outperform Rating	Mar. 04	MT
Wedbush Raises Y-mAbs Therapeutics' PT to $23 From $18 After Higher-Than-Expected Q4 2023 Danyelza Net Product Revenue, Maintains Outperform Rating	Mar. 04	MT
HC Wainwright Adjusts Y-mAbs Therapeutics Price Target to $21 From $11, Maintains Buy Rating	Feb. 20	MT
Wedbush Raises Price Target on Y-mAbs Therapeutics to $18 From $12 After Plans for Phase 1 Cancer Drug Study, Keeps Outperform Rating	Feb. 12	MT
Kempen Upgrades Y-mAbs Therapeutics to Buy From Neutral, Price Target is $10	Dec. 22	MT
JPMorgan Adjusts Y-mAbs Therapeutics Price Target to $7 From $8, Maintains Underweight Rating	23-08-22	MT
Morgan Stanley Adjusts Price Target on Y-mAbs Therapeutics to $5 From $7, Maintains Underweight Rating	23-08-14	MT
Wedbush Trims Y-mAbs Therapeutics' Price Target to $12 From $13, Keeps Outperform Rating	23-08-11	MT
Canaccord Genuity Adjusts Y-mAbs Therapeutics' Price Target to $22 From $21, Keeps Buy Rating	23-07-25	MT
Morgan Stanley Adjusts Price Target on Y-mAbs Therapeutics to $7 From $4, Maintains Underweight Rating	23-05-10	MT
BMO Capital Raises Y-mAbs Therapeutics' Price Target to $15 From $13, Maintains Outperform Rating	23-05-10	MT
Wedbush Upgrades Y-mAbs Therapeutics to Outperform From Neutral, Notes Danyelza Return to Growth Trajectory; Raises PT to $13 From $5	23-05-10	MT
Canaccord Genuity Adjusts Y-mAbs Therapeutics Price Target to $21 From $18, Maintains Buy Rating	23-05-09	MT
HC Wainwright Lowers Price Target on Y-mAbs Therapeutics to $11 From $19, Maintains Buy Rating	23-04-04	MT
Guggenheim Downgrades Y-mAbs Therapeutics to Neutral From Buy	23-04-03	MT
Canaccord Genuity Adjusts Price Target on Y-mAbs Therapeutics to $18 From $20, Maintains Buy Rating	23-03-31	MT
BMO Capital Adjusts Price Target on Y-mAbs Therapeutics to $13 From $12, Maintains Outperform Rating	23-01-30	MT
Morgan Stanley Downgrades Y-mAbs Therapeutics to Underweight From Equal Weight	23-01-27	MT
Cowen Downgrades Y-mAbs Therapeutics to Market Perform From Outperform	23-01-05	MT
Wedbush Lifts Y-mAbs Therapeutics' PT to $5 From $4 After Announced Plan to Reduce Operating Expenses, Keeps Neutral Rating	23-01-05	MT
Wedbush Lowers Y-mAbs Therapeutics' Price Target to $4 From $6, Keeps Neutral Rating	22-11-09	MT
BMO Capital Adjusts Price Target for Y-mAbs Therapeutics to $12 From $29, Keeps Outperform Rating	22-11-01	MT
Kempen Downgrades Y-mAbs Therapeutics to Neutral From Buy, Lowers Price Target to $6 From $20	22-10-31	MT